Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Healthcare Agency Roundtable 2015

Executives from the 2015 and 2014 Manny Award winners and finalists share their views on a variety of industry-related topics.

Read More »

Movember 2015 brings you the Sexy Men of Technology Calendar

More than just humor–it’s humor with a message   Columbus, Ohio – GSW, an industry leader in healthcare advertising and an inVentiv Health company, and LiveTiles, a global technology company headquartered in Times Square, NYC, have partnered to unveil the Sexy Men of Technology Calendar for Movember 2015, a public awareness campaign from the Movember […]

Read More »

Bumper haul of expensive new drugs heads to U.S. and Europe

Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. Drug prices are set to be a major issue in the run-up to the U.S. presidential election next year, with Democratic candidate Hillary […]

Read More »

Sanofi (SNY)’s Ex-Chief Viehbacher Launches Boston Pharma With $600 Million

Cambridge, Mass.-based Gurnet Point Capital announced today that it is launching a new company, Boston Pharmaceuticals, with former Sanofi (SNY) chief executive officer Chris Viehbacher to chair it. Late last year, Viehbacher was ousted by Paris-based Sanofi over battles about strategy with the company’s board. He eventually landed at Gurnet Point Capital in June of […]

Read More »

Roche breast cancer drug at center of UK pricing row

A Roche drug that can prolong the lives of some women with advanced breast cancer has been plunged back into the center of a drug pricing row after Britain’s health cost agency declared that it is still too expensive. The stand-off shows how the price of medicines is as pressing and emotive an issue in […]

Read More »

DARZALEX (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma

    First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent PR Newswire, HORSHAM, PA, November 16, 2015 Janssen Biotech, Inc., a Janssen Pharmaceutical Company of […]

Read More »

U.S. court imposes temporary sales ban on Dr Reddy’s generic Nexium

Dr Reddy’s Laboratories Ltd, India’s second-largest drugmaker by sales, said on Tuesday it had been temporarily barred by a U.S. court from selling its generic form of blockbuster heartburn drug Nexium in the United States. The order was passed by the U.S. district court of Delaware after AstraZeneca, the maker of Nexium, moved a motion […]

Read More »

FDA approves new Novartis dual combination bronchodilator Utibron Neohaler for patients with chronic obstructive pulmonary disease

– Utibron Neohaler (indacaterol/glycopyrrolate) demonstrated superior and sustained improvements in lung function compared to either of its single bronchodilator components as well as placebo, and improved lung function compared to placebo at 5 minutes after the first dose and throughout the dosing interval.1 It does not replace the use of a rescue inhaler – Utibron […]

Read More »

FDA panel votes in favor of approving AstraZeneca’s gout drug

An independent panel of advisers to the U.S. Food and Drug Administration on Friday voted 10-4 in favor of approving AstraZeneca Plc’s gout drug. All 10 who backed the drug, lesinurad, qualified their vote by urging the FDA to ask AstraZeneca for studies after the drug’s launch to gauge its long-term effectiveness and safety. Gout […]

Read More »

FDA clears Merrimack’s pancreatic cancer drug with warning

The U.S. Food and Drug Administration on Thursday approved Merrimack Pharmaceutical Inc’s pancreatic cancer drug, Onivyde, with a severe safety warning. The company’s shares fell as much as 28 percent to a 13-month low of $7.27 in afternoon trade before halving the losses. Onivyde, in combination with chemotherapy treatments 5-fluorouracil and leucovorin, aims to treat […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom